Emcure Pharma set to launch IPO on July 3

Published On 2024-06-30 04:45 GMT   |   Update On 2024-07-16 16:02 GMT
Advertisement

Emcure Pharmaceuticals, backed by Bain Capital, is set to float its Initial Public Offering (IPO) on July 3. The initial share sale will run until July 5, with bidding for anchor investors opening on July 2, as detailed in the Red Herring Prospectus (RHP).

The IPO includes a fresh issuance of equity shares totaling Rs 800 crore and an Offer for Sale (OFS) of 1.14 crore equity shares by promoters and existing shareholders.

Advertisement
According to PTI, those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital.
Currently, Satish Mehta holds a 41.85 per cent stake in the company and BC Investments owns a 13.07 per cent stake.
Proceeds of the fresh issue will be used towards payment of debt and for general corporate purposes.
The Pune-based firm Emcure Pharmaceuticals is engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
Earlier this month, the company received Sebi's go-ahead to float the initial share sale.
Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JP Morgan India are the book-running lead managers to the issue. The equity shares of the company are expected to list on the BSE and NSE on July 10.
Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News